← All trials
NCT04590274
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 5000
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- International Brain Research FoundationLead sponsor
- International Brain Research FoundationOverall official - principal investigator
- International Brain Research FoundationReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.